Tozinameran vaccination in Canada: no change in benefit-risk profile

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
News Item
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907318/
http://dx.doi.org/10.1007/s40278-021-91452-9
_version_ 1783655472279060480
collection PubMed
description
format Online
Article
Text
id pubmed-7907318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79073182021-02-26 Tozinameran vaccination in Canada: no change in benefit-risk profile Reactions Weekly News Item Springer International Publishing 2021-02-27 2021 /pmc/articles/PMC7907318/ http://dx.doi.org/10.1007/s40278-021-91452-9 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
Tozinameran vaccination in Canada: no change in benefit-risk profile
title Tozinameran vaccination in Canada: no change in benefit-risk profile
title_full Tozinameran vaccination in Canada: no change in benefit-risk profile
title_fullStr Tozinameran vaccination in Canada: no change in benefit-risk profile
title_full_unstemmed Tozinameran vaccination in Canada: no change in benefit-risk profile
title_short Tozinameran vaccination in Canada: no change in benefit-risk profile
title_sort tozinameran vaccination in canada: no change in benefit-risk profile
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907318/
http://dx.doi.org/10.1007/s40278-021-91452-9

Ejemplares similares